Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

5 Questions for Martin Steffen, MD, PhD

December 15th 2011

Martin Steffen, MD, PhD, developed phosphorylation signatures that discriminate between lung tumors and normal lung, and is developing signatures for the prediction of therapy response.

Dr. Baselga Describes the Advantages of Dual Blockade

December 14th 2011

Dr. Jose Baselga from Massachusetts General Hospital Describes the Advantages of Dual Blockade

Personalized Medicine Offers Great Hope, Great Challenges

December 14th 2011

Cancer treatment is moving from a one-size-fits-all approach to personalized medicine, which means matching the right drug with the right tumor characteristics.

Channeling His Creativity Into Oncology: A "Renaissance Man" Makes a Mark in Lymphoma Research

December 8th 2011

Andre Goy, MD, MS, treats lymphoma patients at New Jersey's largest cancer center, Goy, 54, is also a translational researcher widely known for his work showing the first-ever evidence of activity of bortezomib.

Emerging Biomarker Science Presents Practical Questions

December 7th 2011

Although the use of tumor markers to evaluate patients with breast cancer is well established, the nuances involved in such testing are growing along with the emergence of novel assays and fresh research findings.

University of Pennsylvania's Abramson Cancer Center: Leaders in Groundbreaking Therapies

December 6th 2011

Established in 1973 as the University of Pennsylvania's Cancer Center and subsequently renamed in 2002, the Abramson Cancer Center is a world leader in research, patient care, and education.

Dr. Mehra Discusses DNA Repair Enzymes

December 5th 2011

Dr. Ranee Mehra from Fox Chase Cancer Center Discusses DNA Repair Enzymes

Not All Viruses Are the Same

December 5th 2011

A look at tweaking the corruptive influence of the virus information code to selectively corrupt cancer cells while sparing (normal) cells that do not have a specific cancer phenotype.

Focusing on EGFR Resistance

December 1st 2011

Ezra E. W. Cohen, MD, has focused on the role of EGFR inhibitors in much of his research into head and neck cancers.

Dr. Markman Discusses Diagnostic Molecular Testing

November 30th 2011

Dr. Maurie Markman from Cancer Treatment Centers of America Discusses Diagnostic Molecular Testing

Pharmaceutical Company Profile: Exact Sciences

November 29th 2011

Analysts are optimistic about Exact Sciences financial losses because they reflect the heavy investment in clinical trials for a new noninvasive colorectal cancer test.

Dr. Cohen Discusses Head and Neck Cancer Pathways

November 29th 2011

Dr. Ezra Cohen from the University of Chicago Discusses Head and Neck Cancer Pathways

The Cleveland Clinic's Taussig Cancer Institute: Patient Experience Reigns Supreme

November 21st 2011

The Cleveland Clinic has long been at the forefront of cutting-edge medicine and research. The center's reputation as a world leader in a multitude of fields, including oncology, is undisputed.

Targeting PI3K/Akt Pathway: 20 Years of Progress

November 21st 2011

This year marks more than 20 years of research into the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway.

Turmeric Ingredient Inhibits Kinase in Cancer Pathway

November 21st 2011

If IKK kinase, a group of inhibitory proteins, activity is not regulated properly, tumors in the body have the ability to migrate and proliferate.

Tumor Angiogenesis: VEGF Pioneer Honored as Quest for Answers Persists

November 18th 2011

The scientific strategy of attacking cancer by thwarting angiogenesis has been on a roller coaster ride for the past 40 years

5 Questions for Josep Tabernero, MD

November 17th 2011

Josep Tabernero, MD, is actively involved in clinical research with molecular targeted therapies, with a focus on EGFR-family and PI3K-Akt-mTOR pathway inhibitors, in phase II and III studies with new chemotherapy agents in gastrointestinal tumors.

A Look at 7 VEGF Inhibitors Currently in Development

November 17th 2011

There are at least 7 drugs specifically targeting VEGF in later-stage clinical trials that have been the subject of presentations at oncology conferences in recent months.

Making Oncology His Path: An Interview With Ezra E.W. Cohen, MD

November 15th 2011

Ezra E. W. Cohen, MD, is a physician and translational researcher at the University of Chicago Medical Center, that focuses on epidermal growth factor receptor (EGFR) inhibitors.

Dr. Goy Explains the Concept of Personalized Medicine

November 4th 2011

Dr. Andre Goy from John Theurer Cancer Center Explains the Concept of Personalized Medicine